TScan Therapeutics Statistics

Total Valuation

TCRX has a market cap or net worth of $100.44 million. The enterprise value is -$68.95 million.

Market Cap	100.44M
Enterprise Value	-68.95M

Important Dates

The last earnings date was Tuesday, August 12, 2025, before market open.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

TCRX has 56.75 million shares outstanding. The number of shares has increased by 7.21% in one year.

Current Share Class	52.47M
Shares Outstanding	56.75M
Shares Change (YoY)	+7.21%
Shares Change (QoQ)	+129.24%
Owned by Insiders (%)	0.76%
Owned by Institutions (%)	54.15%
Float	44.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.43
Forward PS	17.23
PB Ratio	0.57
P/TBV Ratio	0.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-46.38

Financial Efficiency

Return on equity (ROE) is -63.33% and return on invested capital (ROIC) is -34.47%.

Return on Equity (ROE)	-63.33%
Return on Assets (ROA)	-26.77%
Return on Invested Capital (ROIC)	-34.47%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	$35,697
Profits Per Employee	-$701,410
Employee Count	195
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.50% in the last 52 weeks. The beta is 0.99, so TCRX's price volatility has been similar to the market average.

Beta (5Y)	0.99
52-Week Price Change	-70.50%
50-Day Moving Average	1.68
200-Day Moving Average	2.36
Relative Strength Index (RSI)	53.55
Average Volume (20 Days)	265,424

Short Selling Information

The latest short interest is 1.72 million, so 3.03% of the outstanding shares have been sold short.

Short Interest	1.72M
Short Previous Month	1.83M
Short % of Shares Out	3.03%
Short % of Float	3.89%
Short Ratio (days to cover)	5.32

Income Statement

In the last 12 months, TCRX had revenue of $6.96 million and -$136.78 million in losses. Loss per share was -$2.41.

Revenue	6.96M
Gross Profit	-8.57M
Operating Income	-144.24M
Pretax Income	-96.80M
Net Income	-136.78M
EBITDA	-141.14M
EBIT	-144.24M
Loss Per Share	-$2.41

Full Income Statement

Balance Sheet

The company has $169.39 million in cash and n/a in debt, giving a net cash position of $169.39 million or $2.99 per share.

Cash & Cash Equivalents	169.39M
Total Debt	n/a
Net Cash	169.39M
Net Cash Per Share	$2.99
Equity (Book Value)	176.71M
Book Value Per Share	3.11
Working Capital	169.39M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	-123.16%
Operating Margin	-2,072.07%
Pretax Margin	-1,964.88%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.21%
Shareholder Yield	-7.21%
Earnings Yield	-136.17%
FCF Yield	n/a

Analyst Forecast

The average price target for TCRX is $9.50, which is 436.72% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.50
Price Target Difference	436.72%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	114.25%
EPS Growth Forecast (5Y)	-24.27%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1